Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients

Daiqing Gao, Changyou Li, Xihe Xie, Peng Zhao, Xiaofang Wei, Weihong Sun, Hsin Chen Liu, Aris T. Alexandrou, Jennifer Jones, Ronghua Zhao, Jian-Jian Li

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3-5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22. 3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-c and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.

Original languageEnglish (US)
Article numbere93886
JournalPLoS One
Volume9
Issue number4
DOIs
StatePublished - Apr 3 2014

Fingerprint

Cytokine-Induced Killer Cells
stomach neoplasms
immunotherapy
dendritic cells
colorectal neoplasms
Immunotherapy
Dendritic Cells
Stomach Neoplasms
cell viability
Tumors
Colorectal Neoplasms
Cell Survival
cytokines
Cytokines
neoplasms
Neoplasms
Radiotherapy
radiotherapy
Interleukin-2
Disease Progression

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. / Gao, Daiqing; Li, Changyou; Xie, Xihe; Zhao, Peng; Wei, Xiaofang; Sun, Weihong; Liu, Hsin Chen; Alexandrou, Aris T.; Jones, Jennifer; Zhao, Ronghua; Li, Jian-Jian.

In: PLoS One, Vol. 9, No. 4, e93886, 03.04.2014.

Research output: Contribution to journalArticle

Gao, Daiqing ; Li, Changyou ; Xie, Xihe ; Zhao, Peng ; Wei, Xiaofang ; Sun, Weihong ; Liu, Hsin Chen ; Alexandrou, Aris T. ; Jones, Jennifer ; Zhao, Ronghua ; Li, Jian-Jian. / Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. In: PLoS One. 2014 ; Vol. 9, No. 4.
@article{06ecaf6bea704b4198bc4009af9c1df9,
title = "Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients",
abstract = "Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3-5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22. 3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-c and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.",
author = "Daiqing Gao and Changyou Li and Xihe Xie and Peng Zhao and Xiaofang Wei and Weihong Sun and Liu, {Hsin Chen} and Alexandrou, {Aris T.} and Jennifer Jones and Ronghua Zhao and Jian-Jian Li",
year = "2014",
month = "4",
day = "3",
doi = "10.1371/journal.pone.0093886",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients

AU - Gao, Daiqing

AU - Li, Changyou

AU - Xie, Xihe

AU - Zhao, Peng

AU - Wei, Xiaofang

AU - Sun, Weihong

AU - Liu, Hsin Chen

AU - Alexandrou, Aris T.

AU - Jones, Jennifer

AU - Zhao, Ronghua

AU - Li, Jian-Jian

PY - 2014/4/3

Y1 - 2014/4/3

N2 - Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3-5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22. 3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-c and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.

AB - Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3-5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22. 3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-c and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=84899116386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899116386&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0093886

DO - 10.1371/journal.pone.0093886

M3 - Article

C2 - 24699863

AN - SCOPUS:84899116386

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e93886

ER -